Abstract
The aim of this study was to compare efficacy and safety of Allium Curcuma with glibenclamide in type-2 diabetes mellitus with or without dyslipidemia. Thirty five patients were recruited and randomized into 2 groups for 14 weeks treatment and assessment. One group received study drug, three times two capsules containing 200mg turmeric and 200mg allium extract per day. The other group received 1 capsule of 5mg glibenclamide as standard drug per day. After 14 weeks of treatment patients with allium curcuma treatment showed significant decreased in fasting blood glucose (192.76 versus 141.71mg/dL) and 2hours post-prandial blood glucose (295.35 versus 204.35mg/dL). HbA1C level was also significantly decreased (10.41 versus8.09). No difference was found in blood pressure, hematology profile, liver and kidney function of both groups. In conclusion, allium curcuma has potential to be used as antidiabetic agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
